3755563
doi
10.5281/zenodo.3755563
oai:zenodo.org:3755563
Barbara Engel
Department of Nutritional Sciences, Faculty of Health and Medical Sciences, Duke of Kent Building, University of Surrey, Guildford, Surrey GU2 7TE
Linda V. Thomas
Queen's Avenue, Dorchester, DT1 2EP, formerly at Yakult UK Limited, Odyssey Business Park, West End Road, South Ruislip HA4 6QQ, UK
Paul Grob
Department of Clinical Medicine and Ageing, University of Surrey, Guildford, Surrey GU2 7XH, UK.
Michelle Dobrota Gibbs
Expert Nutrition Works, Whimple, Exeter, EX5 2PP
Peter Williams
Department of Mathematics, University of Surrey, Guildford, Surrey GU2 7XH, UK.
Tamara Fenton
Nutrition and Dietetic Service (Cambridge and Peterborough NHS Foundation Trust), First Floor, Sackville House, Sackville Way, Cambourne, Cambridgeshire, CB23 6HL
Simon de Lusignan
Department of Clinical Medicine and Ageing, University of Surrey, Guildford, Surrey GU2 7XH, UK.
Impact of a Daily Probiotic (Lactobacillus casei Shirota) for 12 Months on the Frequency of Diverticulitis Episodes: Feasibility Study in Primary Care.
John Nichols*
60 Manor Way, Onslow Village, Guildford, Surrey GU2 7RR, UK
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Keywords: Dietary fibre; Diverticulitis; Gastrointestinal symptoms; Lactobacillus casei Shirota; Primary care; Probiotic
<p><strong>Background:</strong>Some small secondary care studies have shown benefits from taking probiotics in diverticular disease. We investigated the feasibility of conducting a year-long probiotic study in primary care.</p>
<p><strong>Methods:</strong>Patients (n=21) with a past history of uncomplicated acute diverticulitis but not currently taking antibiotics were recruited from four general practices. Subjects were asked to take the daily probiotic drink YakultÒ. Probiotic effects were assessed by comparing clinically diagnosed diverticulitis attacks in the 6 months prior to probiotic intervention with the 0-6 and 6-12 month periods after probiotic intervention commenced. Effects on gastrointestinal symptoms were assessed by validated questionnaires at baseline, 6 and 12 months. Diet diaries were also completed.</p>
<p><strong>Results: </strong>Two thirds (14/21) of subjects who demonstrated good adherence in taking the daily probiotic improved symptomatically (p=0.025). Clinical presentations with diverticulitis were down 50% during the study period compared with the 12 months period before (7 vs 14 cases; p=0.021). The mean change in gastrointestinal symptom score improved significantly (p <0.001). Diverticulitis episodes did not correlate with body mass index (BMI), diabetic status or dietary fibre. </p>
<p><strong>Conclusions: </strong>Taking the daily probiotic was associated with a lower rate of clinical presentation with diverticulitis episodes and improvement in gastrointestinal symptoms. Sufficient information is presented to design a definitive trial. However, we recommend inclusion of a method to validate the diagnosis of diverticulitis. It is feasible to recruit and run a study that requires participants to take a daily probiotic drink for a year in a primary care setting.</p>
<p>LACTOPRoD was registered at ClinicalTrials.gov: NCT01609751 in 2012.</p>
Zenodo
2020-03-25
info:eu-repo/semantics/article
3755562
1587154816.270468
569562
md5:38dd89f6fca6b5af6f2ae6c6a72e294a
https://zenodo.org/records/3755563/files/ANPH-02-0016.pdf
public
10.5281/zenodo.3755562
isVersionOf
doi
Archives of Nutrition and Public Health
2
1
1-10
2020-03-25